Polaris - Crestor 40 mg vs Atorvastatin 80 mg for 26 weeks - POLARIS
Study identifier:4522IL/0106
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A 26-week, double blind, randomised, multi-centre, phase IIIb, parallel group study to compare the efficacy and safety of rosuvastatin (40 mg) with atorvastatin (80 mg) in subjects with hypercholesterolaemia and coronary heart disease or CHD risk equivalents
Medical condition
Hypercholesterolemia
Phase
Phase 3
Healthy volunteers
No
Study drug
Rosuvastatin, Atorvastatin
Sex
All
Actual Enrollment
-
Study type
Interventional
Age
45 Years - 75 Years
Date
Study Start Date: 01 Apr 2003
Primary Completion Date: -
Study Completion Date: 01 Sept 2004
Study design
Allocation: None
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2013 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 rosuvastatin (40 mg) | Drug: Rosuvastatin 40mg Other Name: Crestor |
| Active Comparator: 2 atorvastatin (80 mg) | Drug: Atorvastatin 80mg Other Name: Lipitor |
Contacts
Investigators
Principal Investigator
Dr. Lawrence Leiter
St Michaels hospital, Canada
